P. Wood

发表

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

K. Davis, S. Rives, Krysta D Schlis, 2018, The New England journal of medicine.

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

S. Rives, Krysta D Schlis, A. Baruchel, 2021, Journal for ImmunoTherapy of Cancer.

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

S. Grupp, D. Porter, B. Levine, 2013 .

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

D. Teachey, S. Grupp, D. Porter, 2014 .

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

D. Teachey, D. Porter, B. Levine, 2013 .

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.

S. Rives, D. Teachey, S. Grupp, 2021, Blood advances.

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

S. Grupp, B. Levine, C. June, 2019, CPT: pharmacometrics & systems pharmacology.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

S. Grupp, B. Levine, C. June, 2018, Clinical Cancer Research.

Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis

K. Davis, S. Rives, Krysta D Schlis, 2017 .

CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

S. Grupp, B. Levine, C. June, 2017 .

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

S. Grupp, D. Porter, B. Levine, 2016 .

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

S. Grupp, D. Porter, P. Wood, 2018, Journal of Hematology & Oncology.

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

D. Teachey, S. Grupp, D. Porter, 2015 .

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Hans Bitter, Kevin Nguyen, Wendy Winckler, 2018, Nature Medicine.

Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL

D. Teachey, S. Grupp, B. Levine, 2014 .

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

S. Grupp, D. Porter, P. Wood, 2018, Journal of Hematology & Oncology.

Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis

Krysta D Schlis, S. Grupp, B. Levine, 2016 .

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

S. Grupp, D. Porter, B. Levine, 2017, Blood.

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

S. Rives, Krysta D Schlis, A. Baruchel, 2016 .

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.

K. Davis, S. Grupp, C. Keir, 2018, Blood.

Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019

S. Rives, S. Grupp, Birgit Jaitner, 2017 .

A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).

D. Porter, B. Levine, M. Kalos, 2013 .

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

D. Teachey, S. Grupp, D. Porter, 2014 .

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

S. Grupp, D. Porter, B. Levine, 2017, Blood.

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.

K. Davis, S. Grupp, C. Keir, 2018, Blood.